Antibody against tumor necrosis factor-α reduces bortezomib-induced allodynia in a rat model.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Anticancer Research

• Publication date

  2013-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 24324081
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lenalidomide in patients with chemotherapy‐induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single‐centre prospective study

  2013cited by this paper
• CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats

  2012cited by this paper
• Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma

  2012cited by this paper
• Myelin structure is unaltered in chemotherapy-induced peripheral neuropathy.

  2012cited by this paper
• Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy.

  2012cited by this paper
• Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

  2012cited by this paper
• TNF-α inhibitors with anti-oxidative stress activity from natural products.

  2012cited by this paper
• Sensory Neurons, Ion Channels, Inflammation and the Onset of Neuropathic Pain

  2012cited by this paper
• Epidural Administration of Spinal Nerves With the Tumor Necrosis Factor-Alpha Inhibitor, Etanercept, Compared With Dexamethasone for Treatment of Sciatica in Patients With Lumbar Spinal Stenosis: A Prospective Randomized Study

  2012cited by this paper
• Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

  2011cited by this paper
• Functional Recovery after Peripheral Nerve Injury is Dependent on the Pro-Inflammatory Cytokines IL-1β and TNF: Implications for Neuropathic Pain

  2011cited by this paper
• Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

  2011cited by this paper
• Chemotherapy‐induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale

  2011cited by this paper
• Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.

  2011cited by this paper
• Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma

  2011cited by this paper
• Anti-TNF-Alpha Therapy Enhances the Effects of Enzyme Replacement Therapy in Rats with Mucopolysaccharidosis Type VI

  2011cited by this paper
• Genetic variation associated with bortezomib-induced peripheral neuropathy

  2011cited by this paper
• Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

  2010cited by this paper
• Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools.

  2010cited by this paper
• TNF-α and neuropathic pain - a review

  2010cited by this paper
• Bortezomib Sensitizes Human Esophageal Squamous Cell Carcinoma Cells to TRAIL–Mediated Apoptosis via Activation of Both Extrinsic and Intrinsic Apoptosis Pathways

  2010cited by this paper
• Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons

  2010cited by this paper
• Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

  2010cited by this paper
• Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.

  2010cited by this paper
• Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

  2010cited by this paper
• Bortezomib‐induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats

  2010cited by this paper
• Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies.

  2010cited by this paper
• Bortezomib: a review of its use in patients with multiple myeloma.

  2009cited by this paper
• Evidence for the prevention of enthesitis in HLA-B27/hβ2m transgenic rats treated with a monoclonal antibody against TNF-α

  2009cited by this paper
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  2008cited by this paper
• Immune-mediated neuropathies in myeloma patients treated with bortezomib.

  2008cited by this paper
• Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma

  2007cited by this paper
• Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

  2007cited by this paper
• Bortezomib-induced peripheral neurotoxicity: still far from a painless gain

  2007cited by this paper
• [Autoimmune aspects of treatment with TNF-alpha inhibitors].

  2007cited by this paper
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

  2006cited by this paper
• Proteasome inhibition in multiple myeloma.

  2006cited by this paper
• The Treatment of Disc Herniation-Induced Sciatica With Infliximab: One-Year Follow-up Results of FIRST II, a Randomized Controlled Trial

  2006cited by this paper
• Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

  2006cited by this paper
• The Treatment of Disc Herniation-Induced Sciatica With Infliximab: Results of a Randomized, Controlled, 3-Month Follow-up Study

  2005cited by this paper
• Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats.

  2005cited by this paper
• Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis.

  2005cited by this paper
• Antimyeloma activity of heat shock protein-90 inhibition.

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia.

  2004cited by this paper
• Wallerian degeneration after crush injury of rat sciatic nerve increases endo- and epineurial tumor necrosis factor-alpha protein.

  2004cited by this paper
• Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• TNF-alpha expression in painful and nonpainful neuropathies

  2001cited by this paper
• Upregulation and interaction of TNFalpha and gelatinases A and B in painful peripheral nerve injury.

  2000cited by this paper
• Upregulation And Interaction Of TNFα and Gelatinases A and B In Painful Peripheral Nerve Injury

  2000cited by this paper
• Serial determination of tumor necrosis factor-alpha content in rat sciatic nerve after chronic constriction injury.

  1999cited by this paper
• Neurotoxicity of isolated limb perfusion with tumor necrosis factor.

  1998cited by this paper
• Prosaptide prevents hyperalgesia and reduces peripheral TNFR1 expression following TNF‐α nerve injection

  1998cited by this paper
• Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1.

  1998cited by this paper
• Changes in plasma cytokines associated with peripheral nerve injury.

  1992cited by this paper
• A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia

  1987cited by this paper

• The Complexity of Neuropathic Pain and Central Sensitization: Exploring Mechanisms and Therapeutic Prospects.

  2024cites this paper
• Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain

  2022cites this paper
• Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy

  2021cites this paper
• Cannabinoids: an Effective Treatment for Chemotherapy-Induced Peripheral Neurotoxicity?

  2021cites this paper
• Chemotherapy‐induced peripheral neuropathy: Identifying the research gaps and associated changes to clinical trial design

  2020cites this paper
• Vincristine- and bortezomib-induced neuropathies - from bedside to bench and back.

  2020cites this paper
• Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects

  2020cites this paper
• Inhibition of microRNA-155 Reduces Neuropathic Pain During Chemotherapeutic Bortezomib via Engagement of Neuroinflammation

  2020cites this paper
• Comparison of Chemotherapy Effects on Mechanical Sensitivity and Food-Maintained Operant Responding in Male and Female Rats

  2019cites this paper
• Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment

  2019cites this paper
• Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-α

  2019cites this paper
• High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats

  2018cites this paper
• Blocking TRPA1 and TNF-α Signal Improves Bortezomib-Induced Neuropathic Pain

  2018cites this paper
• Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy

  2017cites this paper
• Chemotherapy-induced peripheral neuropathy: an update on the current understanding

  2016cites this paper
• Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats.

  2015cites this paper
• Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?

  2015cites this paper
• An Overview of Bortezomib-Induced Neurotoxicity

  2015cites this paper
• Biothérapies anti-TNF-α et douleur

  2015cites this paper
• Pain in cancer survivors

  2014cites this paper
• Bortezomib-induced peripheral neurotoxicity: an update

  2014cites this paper
• Mechanisms of Astrocyte Contribution to Bortezomib-Induced Peripheral Neuropathy

  2014cites this paper